Yunkang Group Past Earnings Performance
Past criteria checks 0/6
Yunkang Group's earnings have been declining at an average annual rate of -31.8%, while the Healthcare industry saw earnings growing at 9.9% annually. Revenues have been declining at an average rate of 72.2% per year.
Key information
-31.8%
Earnings growth rate
-32.9%
EPS growth rate
| Healthcare Industry Growth | 11.3% |
| Revenue growth rate | -72.2% |
| Return on equity | -14.3% |
| Net Margin | -34.9% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Yunkang Group Limited's (HKG:2325) Shareholders Might Be Looking For Exit
Jul 05
Some Yunkang Group Limited (HKG:2325) Analysts Just Made A Major Cut To Next Year's Estimates
Apr 04Estimating The Intrinsic Value Of Yunkang Group Limited (HKG:2325)
Sep 06Why We're Not Concerned About Yunkang Group Limited's (HKG:2325) Share Price
Jul 22We Think You Should Be Aware Of Some Concerning Factors In Yunkang Group's (HKG:2325) Earnings
Sep 29Yunkang Group Limited (HKG:2325) Shares Could Be 37% Below Their Intrinsic Value Estimate
Aug 19Revenue & Expenses Breakdown
How Yunkang Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 795 | -277 | 469 | 0 |
| 31 Mar 24 | 843 | -190 | 458 | 0 |
| 31 Dec 23 | 892 | -102 | 447 | 0 |
| 30 Sep 23 | 1,873 | 45 | 576 | 0 |
| 30 Jun 23 | 2,854 | 192 | 706 | 0 |
| 31 Mar 23 | 3,305 | 284 | 796 | 0 |
| 31 Dec 22 | 3,756 | 377 | 886 | 0 |
| 30 Sep 22 | 3,037 | 418 | 745 | 0 |
| 30 Jun 22 | 2,317 | 459 | 604 | 0 |
| 31 Mar 22 | 2,007 | 415 | 526 | 0 |
| 31 Dec 21 | 1,697 | 372 | 448 | 0 |
| 31 Dec 20 | 1,200 | 265 | 329 | 0 |
| 31 Dec 19 | 678 | -11 | 312 | 0 |
| 31 Dec 18 | 596 | -28 | 293 | 0 |
Quality Earnings: 2325 is currently unprofitable.
Growing Profit Margin: 2325 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2325 is unprofitable, and losses have increased over the past 5 years at a rate of 31.8% per year.
Accelerating Growth: Unable to compare 2325's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2325 is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (-11.6%).
Return on Equity
High ROE: 2325 has a negative Return on Equity (-14.33%), as it is currently unprofitable.